Laboratory persistence and clinical progression of small monoclonal abnormalities

43Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) that presents with no quantifiable M spike on immunofixation electrophoresis (IFE) can be termed IFE MGUS. We retrospectively identified patients with IFE MGUS who were monitored with at least 1 subsequent assessment that included an IFE, and evaluated the persistence of the monoclonal protein and the progression of disease. Although the monoclonal proteins persisted in the majority of patients, 16% did not experience this persistence, and had no documented immunomodulatory therapy. After a median follow-up of 3.9 years, the disease clinically progressed in 14 patients (3.2%). Eight of these 14 patients with clinical progression had an immunoglobulin (Ig) A IFE M protein and 6 had an IgG M protein. This study demonstrates that in some patients with IFE MGUS, the M proteins are transient and that IgA IFE MGUS is more likely to persist and progress to myeloma. © American Society for Clinical Pathology.

Cite

CITATION STYLE

APA

Murray, D. L., Seningen, J. L., Dispenzieri, A., Snyder, M. R., Kyle, R. A., Rajkumar, S. V., & Katzmann, J. A. (2012). Laboratory persistence and clinical progression of small monoclonal abnormalities. American Journal of Clinical Pathology, 138(4), 609–613. https://doi.org/10.1309/AJCPT6OWWMHITA1Y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free